CreatorsPublishersAdvertisers
View more in
Lebanon, NH

Repligen sees $150M Avitide acquisition as key to reaching gene therapy goals

MedCity News
 28 days ago

Cover picture for the articleAvitide, a company that spun out of an Ivy League lab with a way to quickly and efficiently purify biologic drugs, is being acquired for $150 million by global bioprocessing vendor Repligen, which aims to use the technology to bolster its offerings to gene therapy developers. Lebanon, New Hampshire-based Avitide...

medcitynews.com

Comments / 0

Comments / 0